Clinical trials: Placebo Effect
Heart Failure Acute, Heart Failure，Congestive
Effects of Empagliflozin on Clinical Outcomes in Patients With Acute Decompensated Heart Failure
Acute decompensated heart failure is the fastest growing disease in the world and the leading cause of hospital admissions worldwide.
- Conditions
- Heart Failure Acute, Heart Failure，Congestive, Heart Failure; With Decompensation
- Trial name
- EMPA-RESPONSE (NCT03200860)
- Testing
- Empagliflozin 10 MG
- Where
- 5 sites in Netherlands
- Volunteers
- 80 people
- Sponsor
- University Medical Center Groningen
Lipid Metabolism, Inborn Errors, Hyperlipidemias
Measure Liver Fat Content After ISIS 301012 (Mipomersen) Administration
This study will assess what, if any, effect that ISIS 301012 (mipomersen) has on liver triglyceride content in multiple groups of subjects with varying degrees of risk for hepatic steatosis.
- Conditions
- Lipid Metabolism, Inborn Errors, Hyperlipidemias, Metabolic Diseases, Hypolipoproteinemia
- Trial name
- NCT00362180
- Testing
- mipomersen
- Where
- Netherlands
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Kastle Therapeutics, LLC
Muscle Wasting, Non-Small Cell Lung Cancer
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum
The purpose of this study is to determine if the investigational drug GTx-024 can help patients with non small cell lung cancer increase physical function and maintain or gain muscle.
- Trial name
- NCT01355497
- Testing
- GTx-024
- Where
- 30 sites in United States
- Volunteers
- 330 people
- Sponsor
- GTx
Type 2 Diabetes Mellitus, CKD and Albuminuria
A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD
The purpose of this clinical research study is to determine whether dapagliflozin alone or in combination with saxagliptin can decrease albuminuria and improve glycemic control in patients with Type 2 diabetes, albuminuria and…
- Trial name
- NCT02547935
- Testing
- Dapagliflozin 10 mg, Saxagliptin 2.5 mg
- Where
- 112 sites in United States, Australia and 7 more
- Volunteers
- 459 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease
The purpose of this study is to determine if fluticasone furoate/vilanterol improves survival in patients with chronic obstructive pulmonary disease with a history of or increased risk of heart disease.
- Trial name
- NCT01313676
- Testing
- fluticasone furoate/vilanterol, fluticasone furoate, vilanterol
- Where
- 1,611 sites in United States, Argentina and 42 more
- Volunteers
- 16,568 people
- Sponsor
- GlaxoSmithKline
Fibromyalgia
An fMRI Study Of Brain Response In Patients With Fibromyalgia
The purpose of this study is to explore how pregabalin works in patients with fibromyalgia by evaluating brain imaging signals. To find out whether fMRI (functional magnetic resonance imaging) is an efficient way to show whether…
- Trial name
- NCT00760474
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Major Depressive Disorder
Neurobiological Bases of Placebo Response in Major Depressive Disorder
We are doing this research study to find out if people who get better while taking a specific kind of antidepressant medication (a selective serotonin reuptake inhibitor, or SSRI) and people who get better while taking placebo…
- Trial name
- NCT01787240
- Testing
- Escitalopram 10mg
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Rhinitis, Allergic, Perennial and/or Seasonal
Nasacort AQ Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Children With Allergic Rhinitis
The primary objective was to evaluate the effect of a 6-week treatment with TAA-AQ (110 μg) and TAA-AQ (220 μg) once daily (QD) versus placebo on hypothalamic-pituitary-adrenal (HPA) axis function as measured by serum cortisol…
- Trial name
- NCT01154153
- Testing
- Triamcinolone acetonide aqueous (TAA-AQ) nasal spray (NASACORT AQ), Claritin® Syrup
- Where
- 8 sites in United States
- Volunteers
- 140 people
- Sponsor
- Sanofi
Renal Insufficiency, Chronic, Hyperkalemia
A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia
The purpose of this study is to evaluate the effect of Sodium Zirconium Cyclosilicate (SZC), as adjunct to ACEi/ARB therapy (lisinopril or valsartan), on slowing CKD progression (assessed as the reduction in participant's…
- Trial name
- STABILIZE-CKD (NCT05056727)
- Testing
- Sodium Zirconium Cyclosilicate (SZC), Lisinopril, Valsartan
- Where
- 276 sites in United States, Argentina and 19 more
- Volunteers
- 1,112 people
- Sponsor
- AstraZeneca
Asthma
Study Evaluating the Effect of IMA-638 in Subjects With Persistent Asthma
Primary purpose is to assess if IMA-638 is safe and improves asthma in subjects with persistent asthma.
- Trial name
- NCT00425061
- Testing
- IMA-638
- Where
- 82 sites in United States, Canada
- Volunteers
- 159 people
- Sponsor
- Pfizer
Healthy Volunteer Study
Safety, Tolerability,Pharmacokinetics and Pharmacodynamics of ODM-106 in Healthy Volunteers
The study is a dose escalation study with 8 planned dose levels. The study is a 4-period crossover design where each healthy volunteer will be randomised to receive three dose levels of ODM-106 (single doses) and one dose of…
- Trial name
- FIMPAM (NCT02393950)
- Testing
- ODM-106
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Orion Corporation, Orion Pharma
Major Depressive Disorder
Study to Evaluate the Effect and Safety of Quetiapine Extended Release (XR) (FK949E) in Major Depressive Disorder
In this study, quetiapine XR or placebo will be administered orally for 6 weeks to major depressive disorder patients with lack of response to existing antidepressants, with the aim of evaluating the efficacy of quetiapine XR and…
- Trial name
- NCT01725282
- Testing
- quetiapine extended release (XR)
- Where
- 3 sites in Japan
- Volunteers
- 172 people
- Sponsor
- Astellas Pharma Inc
Major Depressive Disorder
Placebo Effects in the Treatment of Depression: Cognitive and Neural Mechanisms
Studies of the neural mechanisms underlying placebo effects in antidepressant clinical trials largely have been limited to demonstrating objective differences in brain activity between responders and non-responders to placebo.
- Trial name
- NCT01919216
- Testing
- Citalopram
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN Study
This is a randomized, double-blind, double-dummy, placebo-controlled, cross over design trial with empagliflozin compared to placebo that is added to open-label ramipril.
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Obesity
- Trial name
- NCT02632747
- Testing
- Empagliflozin, ramipril
- Where
- Canada
- Volunteers
- 31 people
- Sponsor
- Boehringer Ingelheim
Attention Deficit Hyperactivity Disorder
CONCERTA Lab School Study
The purpose of this trial is to determine if the study medication, CONCERTA (methylphenidate HCl), is safe and effective in improving academic performance and behavior in children with Attention Deficit Hyperactivity Disorder…
- Trial name
- NCT00799487
- Where
- 3 sites in United States
- Volunteers
- 89 people
- Sponsor
- Ortho-McNeil Janssen Scientific Affairs, LLC
Ketamine-Induced Brain Activity Changes, Psychotic-like Symptoms
Effects of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Well as Psychotic-Like Symptoms in Healthy Male Adults
The purpose of this study is to determine whether ketamine-induced brain activity changes are modulated by TAK-063 administration using neuroimaging battery tests.
- Trial name
- NCT01892189
- Testing
- Ketamine, TAK-063
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Takeda
Nerve Block, Pain, Postoperative
Pudendal Nerve Block in Vaginal Surgery
The objective of this this randomized controlled study is to determine whether a pudendal nerve block at the time of vaginal surgery is associated with improved postoperative pain control and decrease opioid consumption compared…
- Conditions
- Nerve Block, Pain, Postoperative, Pelvic Floor Disorders, Pelvic Organ Prolapse
- Trial name
- NCT04198714
- Testing
- Pudendal block
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- MetroHealth Medical Center
Obesity
Study of Low Level Laser Therapy to Reduce Body Circumference in Obese Individuals
The purpose of this study is to determine whether low level laser light therapy is effective in reducing circumference of the waist, hips and upper abdomen in obese individuals.
- Trial name
- NCT01821352
- Testing
- Erchonia Obesity Laser
- Where
- 2 sites in United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Erchonia Corporation
Relapsing Remitting Multiple Sclerosis
Assessment Study of Steroid Effect in Relapsing Multiple Sclerosis Subjects Treated With Glatiramer Acetate
This is a study evaluating the effect on brain volume of daily glatiramer acetate (GA) and add-on pulse steroids.
- Trial name
- ASSERT (NCT00203047)
- Testing
- Glatiramer Acetate, Prednisone
- Volunteers
- 414 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Driving Impaired
Driving Simulation to Assess Non-Sedative Effects of Tolperisone
This is a randomized blinded study to assess the sedative effect of 150 mg TID tolperisone and 10 mg TID cyclobenzaprine compared to placebo on simulated driving performance and cognitive functioning in healthy adult volunteers.
- Trial name
- NCT03353922
- Testing
- Cyclobenzaprine 10 Mg Oral Tablet
- Where
- 2 sites in United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Neurana Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.